Proteiinin syntetisoinnissa käytetyn aminohapon epäpuhtaudet
Tuotetiedot
| NO | Tuotteet | CAS NO | Avaimenlaadun ilmaisin | |||
| Puhtaus | Enintään epäpuhtaus | Liuotinjäännökset | Kosteus | |||
| 1 | FMOC-β-ALA-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 2 | Fmoc-D-Ala-D-Ala-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 3 | FMOC-β-ALA-D-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 4 | Fmoc-arg (pbf) -arg (pbf) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 5 | FMOC-β-ALA-Arg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 6 | Fmoc-d-arg (pbf) -d-arg (pbf) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 7 | Fmoc-β-Ala-D-Arg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 8 | Fmoc-homoarg (pbf) -homoarg (pbf) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 9 | Fmoc-β-Ala-Homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 10 | Fmoc-asn (trt) -asn (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 11 | Fmoc-β-ALA-ASN (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 12 | Fmoc-asp (otbu) -asp (otbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 13 | Fmoc-β-ALAP (OTBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 14 | Fmoc-cys (trt) -cys (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 15 | Fmoc-β-Ala-Cys (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 16 | Fmoc-cys (ACM) -cys (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 17 | Fmoc-β-Ala-Cys (ACM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 18 | Fmoc-gln (trt) -gln (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 19 | Fmoc-β-ALA-GLN (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 20 | Fmoc-glu (otbu) -glu (otbu) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 21 | Fmoc-β-ALA-Glu (OTBU) -OH.H2O | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 22 | Fmoc-β-Ala-Gly-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 23 | Fmoc-his (trt) -His (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 24 | Fmoc-β-ala-His (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 25 | Fmoc-Ele-Ele-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 26 | FMOC-β-ALA-ILE-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 27 | Fmoc-Leu-Leu-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 28 | FMOC-β-ALA-LEU-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 29 | Fmoc-d-leu-d-leu-oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 30 | Fmoc-β-Ala-D-Leu-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 31 | Fmoc-lys (BOC) -Lys (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 32 | Fmoc-β-al-lys (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 33 | Fmoc-lys (alloc)-lys (alloc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 34 | Fmoc-β-al-lys (alloc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 35 | Fmoc-Met-Met-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 36 | Fmoc-β-Ala-Met-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 37 | Fmoc-sorn (boc) -orn (boc) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 38 | FMOC-β-ALA-SOR (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 39 | Fmoc-phe-phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 40 | Fmoc-β-Ala-phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 41 | Fmoc-d-phe-d-phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 42 | Fmoc-β-Ala-D-Phe-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 43 | Fmoc-Pro-Pro-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 44 | FMOC-β-ALA-Pro-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 45 | Fmoc-Ser (TBU) -ser (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 46 | Fmoc-β-Ala-Ser (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 47 | Fmoc-ser (trt) -ser (trt) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 48 | Fmoc-β-Ala-Ser (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 49 | Fmoc-thr (tbu) -TH (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 50 | FMOC-β-ALA-Thr (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 51 | Fmoc-TRP (BOC) -TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 53 | Fmoc-d-trp (BOC) -D-TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 55 | Fmoc-TekR (TBU) -Tyr (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 56 | Fmoc-β-ALA-TER (TBU) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 57 | Fmoc-d-Tyr (et) -d-Tyr (et) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 58 | FMOC-β-ALA-D-TER (ET) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 59 | Fmoc-tyr (me) -tyr (me) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 60 | Fmoc-β-ALA-TER (ME) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 61 | Fmoc-val-Val-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 62 | FMOC-β-ALA-Val-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 63 | Fmoc-d-cit-d-cit-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 64 | Fmoc-β-Ala-d-cit-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 65 | Fmoc-β-Ala-Dab-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 66 | Fmoc- (3- (2-naftyyli) -D-Ala) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 67 | FMOC-β-ALA-3- (2-naftyyli) -D-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 68 | Fmoc- (3- (3-pyridinyyli) -D-Ala) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 69 | FMOC-β-ALA-3- (3-pyridinyyli) -D-ALA-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 70 | Fmoc- (4-kloori-d-phe) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 71 | FMOC-β-ALA-4-kloori-D-PHE-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 72 | Fmoc- (D-4Aph (TBUCBM)) 2-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 73 | FMOC-β-ALA-D-4APH (TBUCBM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 74 | Fmoc-aph (l-hor) -aph (l-hor) -oh | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 75 | Fmoc-β-APAPH (L-HOR) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 76 | Fmoc-lys (IPR, BOC) -Lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 77 | Fmoc-β-al-lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 78 | FMOC-β-ALA-Aeea-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 79 | Fmoc-AIB-AIB-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 80 | Fmoc-β-ALA-AIB-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 82 | H-Arg (PBF) -OH | 200115-86-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 83 | Fmoc-d-arg-Oh | 130752-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 84 | HD-Arg (PBF) -OH | 200116-81-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 85 | Fmoc-Homoarg-OH.HCL | 208174-14-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 86 | H-HOMOARG (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 87 | Fmoc-d-Homoarg-OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 88 | HD-Homoarg (PBF) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 89 | Fmoc-Asn-OH | 71989-16-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 90 | H-Asn (TRT) -OH | 132388-58-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 91 | Fmoc-ASP-OH | 119062-05-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 92 | H-ASP (OTBU) -OH | 3057-74-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 93 | Fmoc-Cys-OH | 135248-89-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 94 | H-Cys (TRT) -OH | 2799/7/7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 95 | H-Cys (ACM) -OH.HCL | 28798-28-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 97 | H-GLN (TRT) -OH | 102747-84-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 98 | Fmoc-glu-Oh | 121343-82-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 99 | H-glu (otbu) -oh.h2o | 2419-56-9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 100 | Fmoc-His-OH | 116611-64-4 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 101 | H-His (TRT) -OH | 35146-32-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 102 | Boc-His-OH | 17791-52-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 103 | Fmoc-lys-Oh | 105047-45-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 104 | H-lays (BOC) -OH | 2418-95-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 105 | H-lays (alloc) -oh | 6298/3/9 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 106 | Fmoc-sorn-oh.hcl | 201046-57-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 107 | H-Sorn (BOC) -OH | 13650-49-2 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 108 | Fmoc-Ser-OH | 73724-45-5 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 109 | H-SER (TBU) -OH | 18822-58-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 110 | H-SER (TRT) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 112 | H-Thr (TBU) -OH | 4378-13-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 113 | Fmoc-TRP-OH | 35737-15-6 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 114 | H-Trp (BOC) -OH | 146645-63-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 115 | Fmoc-D-TRP-OH | 86123-11-7 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 117 | Fmoc-TER-OH | 92954-90-0 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 118 | H-Tyr (TBU) -OH | 18822-59-8 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 119 | Fmoc-d-Tyr-OH | 112883-29-1 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 120 | HD-Tyr (et) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 121 | H-Tyr (ME) -OH.HCL | 67423-44-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 122 | Fmoc-d-4aph (CBM) -OH | 324017-22-3 | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 123 | HD-4APH (TBUCBM) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 124 | Fmoc-lys (IPR) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
| 125 | H-lys (IPR, BOC) -OH | NA | ≥98,0% | ≤1,0% | ≤8,0% | ≤2,0% |
Noin
Korvaus
Gentolex tarjoaa korkealaatuisia tuotteita, jos asiakas korottaa tuotteen laatua vaaditussa aikataulussa riittävillä todisteilla, tarjoamme tarvittavan analyysin ja arvioinnin kompensointimenettelyjen käynnistämiseksi.
Tuotanto
Farmaseuttisten tuotteiden kapasiteetit saavuttivat tonnin, kemiantuotteiden kapasiteetit saavuttavat 100tons+ -luokan, ominaisuudet on hyvin varustettu palvelemaan asiakkaita ympäri maailmaa.
Tutkimus ja kehitys
Joka vuosi T & K -tiimi on suunniteltu kehittämään erilaisia uusia tuotteita, kun tavoitteet asetetaan, jokaisen ryhmän jäsenen on jatkettava KPI -vastuun ja kannustinpolitiikan avulla.
